Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Latest Information Update: 16 Mar 2023
At a glance
- Drugs Atezolizumab (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia; Richter's syndrome
- Focus Therapeutic Use
- 13 Mar 2023 Planned End Date changed from 28 Feb 2023 to 28 Feb 2025.
- 13 Mar 2023 Planned primary completion date changed from 28 Feb 2023 to 28 Feb 2025.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition